Accessibility

Our global life sciences company brings diagnostic testing & drug development together.

Labcorp.com

About Vectra by Labcorp

Vectra, used with provider and patient assessments, helps guide better patient outcomes.

Rheumatoid arthritis (RA) is a systemic disease that can be difficult to manage. Providers can add an objective measure to an assessment with Vectra. 

Vectra provides a personalized score by measuring 12 biomarkers and incorporating information on age, gender and adiposity to measure your patients’ RA inflammation and predict their risk of radiographic progression.

People laughing

Clinical Use of Vectra by Labcorp

How Vectra can help guide decision-making

Unsurpassed Predictor of Radiographic Progression

Up to 42% of patients thought to be in low or moderate disease activity were found to be in high disease activity when measured by Vectra and at risk for joint damage. Vectra helps you identify risk so you can take action earlier. Vectra helps identify risk so action can be taken earlier.

Management of RA Inflammation

Evaluate the success of controlling inflammation by using Vectra and monitoring the scores over time.

Enhanced Care

An evaluation that combines the molecular measures of biomarkers with the patient and rheumatologist assessments provides the most comprehensive approach to inform treatment decisions.

Molecular Assessment

Enhanced Vectra

Vectra now accounts for age, gender and adiposity for a more personalized score.

Helps Improve Outcomes

Vectra is the best predictor of future joint damage. The Adjusted Vectra Score was validated in four cohorts combined as a superior prognostic of radiographic progression, compared with conventional measures.

Manage to Goal

Vectra can inform the success of treatment when scores are tracked over time. A change in 8 or more units in subsequent Vectra scores reflects a meaningful change and may be considered a tool, combined with a clinical assessment, to optimize treatment decision-making.

Rheumatologists Use Vectra by Labcorp to Inform Treatment Decisions

Evaluate the success of controlling RA inflammation by using Vectra at initiation of treatment, change in drug treatment or to monitor response to therapy.

Test Reports: A Personalized Precision Tool 

The Vectra Report gives a molecular assessment of RA disease. Vectra demonstrates its unsurpassed ability to predict radiographic progression as a personalized inflammatory measure for patients with RA. Vectra is a validated, advanced blood test performed by a CLIA-certified laboratory.

See sample report (coming soon)

The Provider Guide

Download the brochure to learn more about Vectra and how it can help to improve patient and provider decisions.